Hers Semaglutide Review

Hers (by Hims & Hers Health) has emerged as a leading women's telehealth platform, and their weight loss program reflects their understanding of women's unique health needs. Our research (updated July 25, 2026) found a polished, user-friendly platform—now operating under fundamentally different medication economics than its early marketing suggested.

Important 2026 Update: Brand-Name Only

After Hims & Hers settled its litigation with Novo Nordisk in March 2026, the company exited compounded semaglutide for new patients. If you've seen older Hers marketing citing $69/month compounded pricing, that era is over: the weight loss program now offers FDA-approved brand-name medications—Wegovy®, Zepbound®, and related options—on a membership-plus-medication structure similar to its sibling Hims program ($39-range first month, then a monthly clinical membership, with brand medication billed separately by insurance status). For readers wary of compounded medications this is a genuine safety upgrade; for budget cash-pay buyers it removes the low-cost option. Confirm the current all-in quote at signup. What sets Hers apart is their flexibility. With plan options ranging from 1 to 12 months and $0 membership fees, patients aren't locked into long commitments. The 24/7 app access to licensed providers means support is always available, which is particularly valuable for managing medication side effects or concerns. While the platform is designed primarily for women, the clinical expertise behind their weight loss program is solid. Board-certified physicians oversee treatment plans, and the company's broader telehealth experience (they're part of the publicly-traded Hims & Hers Health) provides operational stability.